This chapter discusses the conservative spending within the biotech and bio pharma markets, highlighting the significant annual spending on R&D despite certain scaling back. It also explores the trend of non-dilutive financing and the increase in public to private deals in the life science sector. The chapter emphasizes the potential for continued growth in this area and the challenges faced by companies in raising equity funds.